Forte Biosciences Inc FBRX

Healthcare Biotechnology

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

NDAQ:FBRX - Post by User

Forte Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by ChartHawk92on Nov 27, 2024 4:17pm

13 Views

Post# 36334418

FBRX's Financials Show Solid Foundation

FBRX's P/B ratio of 2.99 indicates a solid financial base. With a $53M cash infusion, the company is well-positioned for growth. Keep this biotech on your watchlist!

<< Previous

Bullboard Posts

Next >>

AI companies to invest in